Royalty-backed financing (Royalty Pharma, Blackstone, DRI Healthcare-style deals) lets pharma companies fund clinical development without equity dilution, but creates a perpetual tax on product revenues that reduces the equity value of the underlying franchise. Unlike conventional debt, the royalty obligation does not appear as interest expense but as a reduction in operating cash flow — making it invisible to analysts screening on P/E or EV/S. The obligation balance must be treated as quasi-debt: subtract from equity value when computing intrinsic worth.
For any pharma company that has used royalty-backed financing, run two valuations: (1) standard EV/S/NI ignoring royalties, (2) adjusted EV adding royalty balance as debt-equivalent. The gap between these two valuations is the "royalty haircut." When the royalty balance exceeds 15-20% of market cap, apply this as an explicit discount to intrinsic value. Screen for disclosure of "royalty financing," "revenue interest financing," or "non-dilutive funding" in 10-K notes as a flag to trigger this adjustment.